As so often, my right hon. Friend, who is one of the most astute medical practitioners in this House—crikey, I could get myself into trouble
there, because all the medical practitioners in this House are astute, but he is also a public health expert. I will start again. My right hon. Friend’s point was a really good one and very astute. He is exactly right about our approach: the two-week review is a data review.
Up to around 10 days to a week before the decision making cut-off for the proposal to take step 4 on 21 June, it looked like hospitalisations were staying flat, despite rising case rates. We did not know whether that was because of a lag or because there was now going to be no cases turning into hospitalisations. That remains the case now for the link to the number of people dying, because the number of people dying each day in England is actually slightly falling at the moment—thank goodness —and there has not been a rise in the number of deaths following the rise in the case rates, which started about three weeks ago. Within a couple of weeks, we will know whether that continues to be flat or whether it rises a little. It has risen a little in Scotland; I just put that warning out there. That is precisely the sort of data that we will be looking at at the two-week point. We have been absolutely clear that the goal on which we hang the decision ahead of 19 July is one of delivering the vaccines, and we have a very high degree of confidence that we can deliver the vaccines that we think are needed in order to be able to take step 4 on 19 July.
I hope that was a clear and comprehensive answer, once I untangled myself from my initial response to my right hon. Friend.